Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse events (AEs) remains unknown. Methods: Patients with stage III NSLCC treated...

Full description

Bibliographic Details
Main Authors: Narek Shaverdian, MD, Michael Offin, MD, Annemarie F. Shepherd, MD, Matthew D. Hellmann, MD, Daniel R. Gomez, MD, Jamie E. Chaft, MD, Andreas Rimner, MD
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:JTO Clinical and Research Reports
Subjects:
Durvalumab
Stage III NSCLC
Chemoradiation
Pneumonitis
Toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000564

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000564

Similar Items